The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

News Headlines and Feed

Business News Videos

Novo Nordisk invests further in China by opening new, bigger research and development centre

Monday, 24 September 2012
The Danish company that is the leading producer insulin in the world, Novo Nordisk A/S, announced on Monday that it will be opening a new science facilities in Beijing that it said will help fuel growth and allow the Danish company to profit from new Chinese diabetes and protein research.

In a press release out on Monday, the company said it has invested $100 million in the 12,000 square meters expansion of its Chinese research centre, which will add another 70 science jobs to its current total of 130 employees.

"We see the investment in this new research and development facility as a win-win opportunity for both Novo Nordisk and China," said Novo Nordisk Chief Science Officer Mads Krogsgaard Thomsen in the press release.

Novo Nordisk first opened research facilities in China in 1997, the first multinational company to do so. It also operates a production plant in Tianjin and has local offices in Shanghai, Guangzhou, Shenyang, Wuhan, Jinan, Hangzhou, Chengdu, Hong Kong and Taiwan and employ some 3,000 people in China.
Read more from the press release here
Scancomark.com

We welcome your contribution. Did you find anything wrong with this article? Do you want to contribute to our news network? Do have a news tip or assist us with a correction